Skip to main content

Advertisement

SpringerLink
Log in

Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

The aims of this study are to analyze the association of microRNA-141 (miR-141) with the clinicopathological parameters of bladder cancer and evaluate the value of miR-141 in predicting the prognosis of bladder cancer. In this study, 114 patients with bladder cancer were enrolled in the study, and tissue specimens were obtained from the tumor zone and from adjacent normal area. miR-141 expression was determined using SYRB Green quantitative real-time polymerase chain reaction assay and was further correlated with patients’ clinicopathological parameters and the follow-up data. The results indicated that miR-141 was upregulated in malignant bladder specimens compared with normal ones (P < 0.001). miR-141 expression was significantly associated with tumor stage (P < 0.001), tumor grade (P < 0.001), and muscle invasion status (P < 0.001). Log-rank test showed that the higher miR-141 expression was associated with longer disease-specific survival of the patients with bladder cancer (P < 0.001), which was also proven by univariate and multivariate Cox regression analysis (P < 0.001 and P = 0.039, respectively). Focusing on patients with non-muscle invasive bladder cancer, univariate analysis using log-rank test and Cox regression analysis found that patients with high miR-141 expression experienced longer disease-free survival (P = 0.031 and P = 0.040, respectively) and disease-specific survival (P = 0.028 and P = 0.038, respectively), which was confirmed by multivariate Cox regression analysis (P = 0.036 and P = 0.042, respectively). In conclusion, this study showed that miR-141 may contribute to the progression of bladder cancer and its upregulation may be independently associated with favorable prognosis of bladder cancer, suggesting that miR-141 might serve as a promising biological marker for further risk stratification in the management of bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Qi F, Liu Y, Zhao R, Zou X, Zhang L, Li J, et al. Quantitation of rare circulating tumor cells by folate receptor alpha ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance. Tumor Biol. 2014;35(7):7217–23.

    Article  CAS  Google Scholar 

  2. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59(6):997–1008.

    Article  PubMed  Google Scholar 

  3. Ratert N, Meyer HA, Jung M, Lioudmer P, Mollenkopf HJ, Wagner I, et al. miRNA profiling identifies candidate miRNAs for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 2013;15(5):695–705.

    Article  CAS  PubMed  Google Scholar 

  4. Sexton WJ, Wiegand LR, Correa JJ, Politis C, Dicknson SI, Kang LC. Bladder cancer: a review of non-muscle invasive disease. Cancer Control. 2010;17(4):256–68.

    PubMed  Google Scholar 

  5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.

    Article  CAS  PubMed  Google Scholar 

  6. Tian L, Li M, Ge J, Guo Y, Sun Y, Liu M, et al. miR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumors. Tumor Biol. 2014;35(6):5953–63.

    Article  CAS  Google Scholar 

  7. Dip N, Reis ST, Timoszczuk LS, Voama NI, Piantino CB, Morais DR, et al. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J Urol. 2012;188(5):1951–6.

    Article  PubMed  Google Scholar 

  8. Cao Y, Yu SL, Wang Y, Guo GY, Ding Q, An RH. MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24. Tumor Biol. 2011;32(1):179–88.

    Article  CAS  Google Scholar 

  9. Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, Lavoie AK, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol. 2011;29(6):794–801.

    Article  CAS  PubMed  Google Scholar 

  10. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat RJ, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639–53.

    Article  PubMed  Google Scholar 

  11. Stenzl A, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59(6):1009–18.

    Article  CAS  PubMed  Google Scholar 

  12. Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 2011;128(6):1327–34.

    Article  CAS  PubMed  Google Scholar 

  13. Ratert N, Meyer HA, Jung M, Mollenkopf HJ, Wagner I, Miller K, et al. Reference miRNAs for miRNAome analysis of urothelial carcinomas. PLoS One. 2012;7(6):e39309.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wang S, Li Q, Wang K, Dai Y, Yang J, Xue S, et al. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clin Transl Oncol. 2013;15(10):849–54.

    Article  CAS  PubMed  Google Scholar 

  15. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3–12.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lv S, Turlova E, Zhao S, Kang H, Han M, Sun SH. Prognostic and clinicopathological significance of surviving expression in bladder cancer patients: a meta-analysis. Tumor Biol. 2014;35(2):1565–74.

    Article  CAS  Google Scholar 

  17. Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2005;66(6 Suppl 1):64–74.

    Article  PubMed  Google Scholar 

  18. Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res. 2007;13(12):354535–51.

    Article  Google Scholar 

  19. Chen D, Zhang YJ, Zhu KW, Wang WC. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumor Biol. 2013;34(3):1895–9.

    Article  CAS  Google Scholar 

  20. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23(15):3526–35.

    Article  CAS  PubMed  Google Scholar 

  21. Maruyama R, Suzuki H, Yamamoto E, Imai K, Shinomura Y. Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer. Tumor Biol. 2012;33(2):277–85.

    Article  CAS  Google Scholar 

  22. Yu XY, Zhang Z, Liu J, Zhan B, Kong CZ. MicroRNA-141 is downregulated in human renal cell carcinoma and regulates cell survival by targeting CDC25B. Onco Targets Ther. 2013;6(1):349–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Yeh TS, Wang F, Chen TC, Yeh CN, Yu MC, Jan YY, et al. Expression profile of microRNA-200 family in hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg. 2014;259(2):346–54.

    Article  PubMed  Google Scholar 

  24. Luo D, Wilson JM, Harvel N, Liu J, Pei L, Huang S, et al. A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. J Transl Med. 2013;11(1):57–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Vega AB, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep. 2013;30(1):320–6.

    CAS  Google Scholar 

  26. Yaman F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol. 2011;32(3):583–8.

    Article  Google Scholar 

  27. Xie P, Xu F, Cheng W, Gao J, Zhang Z, Ge J, et al. Infiltration related miRNAs in bladder urothelial carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2012;32(4):576–80.

    Article  CAS  PubMed  Google Scholar 

  28. Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol. 2014;32(2):353–8.

    Article  CAS  PubMed  Google Scholar 

  29. Yoshino H, Enokida H, Itesako T, Tatarano S, Kinoshita T, Fuse M, et al. Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. J Hum Genet. 2013;58(8):508–16.

    Article  CAS  PubMed  Google Scholar 

  30. Xiong M, Jiang L, Zhou Y, Qiu W, Fang L, Tan R, et al. The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Ren Physiol. 2012;302(3):F369–79.

    Article  CAS  Google Scholar 

  31. Liang HH, Wei PL, Hung CS, Wu CT, Wang W, Huang MT, et al. MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. Tumor Biol. 2013;34(5):3209–18.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from Nantong Technology (HS 2013023) and grants from Special Fund of Nantong Human Resource (W201208).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Urology, Nantong Tumor Hospital, Nantong, 226361, China

    Xiao-Lin Wang, Hu-Yang Xie, Guang-Xin Cao & Xiao-Hong Chen

  2. Department of Oncology, The Second Affiliated Hospital of Southeast University, 1-1 Zhongfu Road, Nanjing, 210003, China

    Chuan-Dong Zhu, Xiao-Fang Zhu & Han-Feng Xu

Authors
  1. Xiao-Lin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hu-Yang Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chuan-Dong Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiao-Fang Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guang-Xin Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiao-Hong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Han-Feng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Han-Feng Xu.

Additional information

Xiao-Lin Wang and Hu-Yang Xie contribute equally for this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, XL., Xie, HY., Zhu, CD. et al. Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer. Tumor Biol. 36, 877–883 (2015). https://doi.org/10.1007/s13277-014-2656-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2656-8

Keywords

Search

Navigation